Skip to main content
. 2017 Feb 13;14(3):784–791. doi: 10.1007/s13311-017-0512-4

Table 1.

Demographic data for cilostazol cohort and comparison cohort (n = 9148)

Variables Comparison cohort (n = 6861) Cilostazol cohort (n = 2287) p-value
n % n %
Age (years)
  < 65 2425 35.3 797 34.8 0.667
  ≥ 65 4436 64.7 1490 65.2
Sex
 Female 3274 47.7 1067 46.7 0.378
 Male 3587 52.3 1220 53.3
Comorbidities
 Diabetes 4047 59.0 1358 59.4 0.740
 Hyperlipidemia 3483 50.8 1174 51.3 0.638
 Hypertension 5540 80.7 1808 79.1 0.078
 Depression 967 14.1 296 12.9 0.167
 Ischemic heart disease 833 12.1 308 13.5 0.096
 Cerebral vascular disease 1416 20.6 478 20.9 0.789
Charlson's index score
  ≤ 1 2019 29.4 681 29.8 0.696
 2 1409 20.5 484 21.2
  ≥ 3 3433 50.0 1122 49.1
Medication
 Anticoagulant agents 115 1.7 45 2.0 0.357
 Antiplatetet agents 1234 18.0 441 19.3 0.165
 Antidiabetic agents 3174 46.3 1046 45.7 0.663
 Antihypertension agents 4866 70.9 1595 69.7 0.283
 Statin 1529 22.3 539 23.6 0.204